Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Guoliang Qiao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109333880. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 10

  1. Systemic Treatment Followed by Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer: A Retrospectively Observa… Co-author DOI 10.1097/sla.0000000000006600↗
  2. Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial. Co-author DOI 10.1200/jco-26-01393↗
  3. 5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center. Co-author DOI 10.1016/j.canlet.2025.217658↗
  4. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. Co-author DOI 10.1016/j.ccell.2025.09.009↗
  5. Efficacy of Neoadjuvant Therapy and the Prognostic Significance of Serum Carcinoembryonic Antigen Level in Patients with Localized Pancreatic Adenocarcinoma wi… Co-author DOI 10.1097/sla.0000000000006719↗
  6. Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.09.041↗
  7. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  8. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  9. Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fonc.2022.837560↗
  10. Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. First author DOI 10.1158/1078-0432.ccr-17-0492↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tianan Jiang · 4 shared papers, 2025–2026 · strength 0.88
  2. Tingbo Liang · 4 shared papers, 2025–2026 · strength 0.84
  3. Motaz Qadan · 4 shared papers, 2022–2025 · strength 0.73
  4. Keith D. Lillemoe · 4 shared papers, 2022–2025 · strength 0.73
  5. Xiang Li · 3 shared papers, 2025 · strength 0.62
  6. Xueli Bai · 3 shared papers, 2025 · strength 0.62
  7. Risheng Que · 3 shared papers, 2025–2026 · strength 0.61
  8. Cristina Rosa Ferrone · 3 shared papers, 2022–2024 · strength 0.51
  9. Xueli Bai · 2 shared papers, 2026 · strength 0.48
  10. Qi Zhang · 2 shared papers, 2025 · strength 0.39
  11. Louisa Bolm · 2 shared papers, 2024–2025 · strength 0.39
  12. Zhi Ven Fong · 2 shared papers, 2024 · strength 0.38
  13. Maximiliano Servín-Rojas · 2 shared papers, 2024 · strength 0.38
  14. Carlos F. Fernandez-del Castillo · 2 shared papers, 2022–2024 · strength 0.34
  15. Tao Ma · 1 shared paper, 2026 · strength 0.26
  16. Xiang Li · 1 shared paper, 2026 · strength 0.26
  17. Qi Zhang · 1 shared paper, 2026 · strength 0.26
  18. Tingbo Liang · 1 shared paper, 2026 · strength 0.26
  19. Xinhui Su · 1 shared paper, 2026 · strength 0.26
  20. Yiwen Chen · 1 shared paper, 2025 · strength 0.22
  21. Zhiyong Yang · 1 shared paper, 2025 · strength 0.22
  22. Xiaozhen Zhang · 1 shared paper, 2026 · strength 0.22
  23. Fidel López‐Verdugo · 1 shared paper, 2024 · strength 0.21
  24. Theodore Sunki Hong · 1 shared paper, 2024 · strength 0.17
  25. Kelsey S. Lau‐Min · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.